Since 2013 Orexo is established in the US with an own sales force. Today US Pharma consists of the lead product ZUBSOLV®, for the treatment of opioid use disorder. On a daily basis our sales representatives visits physicians, medical clinics and minor hospitals with the aim to improve life for people who are dependent on opioids.

The therapies are developed based on established cognitive behavioral therapy technique which is a goal-oriented psychotherapy treatment that takes a hands-on, practical approach to problem solving. The aim is to provide support and change patterns of thinking or behavior that are behind patients difficulties.

Go to our digital therapeutic's product websites

Digital Therapies
Technical development
Registration
Approved and/or Launched
US
EU
RoW
Deprexis® Depression
Partner: GAIA AG
Vorvida® Alcohol misuse, incl. alcohol use disorder
Partner: GAIA AG
MODIA™ Opioid addiction
Partner: GAIA AG
 

Instructions for use

Alcohol misuse

Depression

Opioid dependence

Clinical evidence

Evaluated in 1 randomized clinical trial, > 600 patients 1

Evaluated in 13 randomized clinical trials, > 2.800 patients 2

Ongoing randomized clinical trial, 400 patients

Length of treatment

6 months

3 months

6 months

3 Questions with Dennis Urbaniak, EVP of Digital Therapeutics

Our pipeline of new commercial opportunities was greatly accelerated through new partner- ships, such as SoberGrid, Trinity Health, Justmi- ine, and also with Walgreens, who we signed a collaboration with at the beginning of January 2022. These complementary platforms have created significant new qualified sales opportu- nities to pull through in 2022.

  • Drive growing, sustainable demand in the areas that we have secured billable product access.
  • Expand the overall number of users and market access for all three DTx therapies.
  • Successfully scale our MODIATM launch that began in late Q4, 2021.
  • Leverage our learnings from 2020–2021 to optimize our investments and improve long term ROI.

I would like Orexo to be seen as the industry leader in tangible DTx commercialization, delivering real world outcomes for patients while also ensuring DTx becomes a significant contributor to Orexo’s revenue growth and profitability.

Orexo´s digital therapies are developed together with GAIA AG who is a world leader in digital therapeutics since 2001. Its technology is built on the artificial intelligence (AI) software broca® and simulates interaction between the patient and an empathetic physician or therapist.

GAIA: a world leader in digital therapeutics

  • Proven effectiveness in numerous randomized clinical trials with over 7,000 patients
  • More than 12 years of R&D experience, 20+ CE & FDA compliant products
  • Indications - CNS, immunology, oncology

Source and image rights - GAIA AG

1 Jördis M. Zill, Eva Christalle, Björn Meyer, Martin Härter, and Jörg Dirmaier The Effectiveness of an Internet Intervention Aimed at Reducing Alcohol Consumption in Adults: Results of a Randomized Controlled Trial (Vorvida) Dtsch Arztebl Int 2019; 116: 127–33. DOI: 10.3238/arztebl.2019.0127
2 Twomey et al. (2020), Zwerenz et al. (2017), Berger et al. (2018), Beevers et al. (2017), Klein et al. (2016), Meyer et al. (2015), Moritz et al. (2012), Berger et al. (2011), Meyer et al. (2009), Bücker et al. (2018), Fischer et al. (2015), Schröder et al. (2014)